An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination with Liposomal Doxorubicin in Patients with Ovarian Cancer or Other Advanced Solid Tumors

Trial Profile

An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination with Liposomal Doxorubicin in Patients with Ovarian Cancer or Other Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs STM 434 (Primary) ; Doxorubicin liposomal
  • Indications Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 10 Feb 2017 Status changed from recruiting to completed.
    • 08 Aug 2016 According to an Atara Biotherapeutics media release, the company plans to begin the monotherapy dose expansion component of this trial by the end of 2016 in patients with advanced granulosa cell or clear cell ovarian cancer.
    • 07 Jun 2016 Results (n=22) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top